Stockreport

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG...

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF - Clinical data show benefit of combining immune checkpoint inhibitors in MSS CRC and essential role of CTLA-4 to prime PD-L1 pathway - - Clinical poster selected by [Read more]